Eqvalan Duo

Quick links to important sections

Eqvalan Duo

Method of action: Anthelmintic, Antiparasitic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eqvalan Duo

Property Description
Active Ingredients Ivermectin, Praziquantel
Form Oral Paste (Ready-to-Use Syringe)
Pharmacological Class Broad-Spectrum Anthelmintic
General Purpose Comprehensive Equine Parasite Management
Origin Synthetic Compound
Manufacturer Boehringer Ingelheim Vetmedica GmbH

Eqvalan Duo is a well-recognized veterinary antiparasitic agent administered as a ready-to-use oral paste for equids. It is classified as a fixed-dose combination product within the high-level pharmacological class of broad-spectrum anthelmintics. Unlike many single-active-ingredient dewormers, the product is positioned to provide a comprehensive, single-treatment solution against the most detrimental internal parasites in horses.


Composition and Formulation Differentiators

The therapeutic efficacy of Eqvalan Duo is established by its dual-synthetic composition, featuring Ivermectin and Praziquantel. Ivermectin is a derivative of the macrocyclic lactone class, effective against nematodes (roundworms), while Praziquantel is an isoquinoline derivative targeting cestodes (tapeworms). This dual formulation is recognized for its use in various target groups, including foals from two months of age and pregnant mares after the first trimester. The ready-to-use oral paste format from manufacturer Boehringer Ingelheim Vetmedica GmbH provides a convenient administration method designed for accurate dosing based on the animal's weight.


General Purpose: Integrated Parasite Control

The primary function of Eqvalan Duo is to provide effective, simultaneous control and elimination of mixed infestations caused by both cestodes and nematodes. This combination approach is utilized in veterinary practice as a component of a rotational deworming program. The integrated clearance of the full parasitic burden contributes to maintaining the horse's gut health and overall physiological well-being, mitigating the health risks associated with heavy strongyle and tapeworm loads. This broad-spectrum utility is a defining factor that differentiates it from single-agent formulations.

What side effects are possible with Eqvalan Duo?

Possible Side Effects and Safety Information

The safety profile for Eqvalan Duo is based on classifications within official regulatory documents, defining adverse reactions primarily in the uncommon and very rare frequency categories.


Documented Adverse Reactions and Frequencies

Adverse reactions associated with the product are chiefly related to the Gastrointestinal Disorders system-organ class and General Disorders (e.g., swelling). The most frequently reported events are classified as uncommon, affecting between 1 and 10 individuals per 1,000 treated. These include transient swelling (edema) and inflammation of the mouth, lips, or tongue, as well as hypersalivation (drooling) and pruritus (itching).

Reactions classified as very rare (affecting fewer than 1 in 10,000) include abdominal discomfort (colic) and loose stools or diarrhea. The regulatory label notes that oral reactions are typically transitory in nature, usually resolving within 24 to 48 hours.


Safety Restrictions and Special Populations

Regulatory documents outline specific safety constraints. The product is contraindicated for individuals under two months of age and those with a documented hypersensitivity to Ivermectin, Praziquantel, or any component of the formulation. Use in pregnant individuals is generally permissible after the first three months of gestation and during lactation.

Further constraints include a regulatory withdrawal period of 30 days for individuals intended for human meat consumption. The official safety information also mandates strict caution due to the risk of severe adverse reactions or fatalities if the paste is ingested by non-target species, such as dogs, cats, or certain turtle species.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory text detailing Eqvalan Duo overdose specifies a limited set of clinical manifestations observed in studies, primarily following administration at ten times the recommended dose in adult horses. The overall overdose profile is one of transient severity, based on government-authorized documentation.

Documented Overdose Presentations

The documented signs of overdose include transient decreased food consumption, increased body temperature, salivation, and temporary impairment of vision. These clinical changes were universally observed to be transient and resolved spontaneously, typically disappearing within five days of the overdose event.

Emergency Response and Antidote Information

The regulatory documentation explicitly states that no specific antidote has been identified for Eqvalan Duo overdose. Consequently, management is directed toward symptomatic therapy, which is listed as potentially beneficial.

Population-Specific Tolerance and Help-Seeking

Regulatory studies also note population-specific tolerance, indicating that no undesirable effects were observed in horses as young as two months of age when treated at up to three times the recommended dose. Because the documented manifestations are transient and self-resolving, the official label does not explicitly define conditions under which immediate emergency veterinary attention must be sought for the animal based on the presence of these specific signs.

Therapeutic Uses of Eqvalan Duo

What Eqvalan Duo Treats: Main Uses and Benefits

Eqvalan Duo is primarily used in situations involving certain distressing symptoms that arise from widespread internal parasite infestations in equids. The combination is explicitly indicated for the treatment of mixed cestode and nematode or arthropod infestations.


Key Therapeutic Domains

This medication is applied across domains where additional symptomatic support is needed, specifically targeting infections caused by key internal parasites. The primary therapeutic areas include tapeworms (Anoplocephala spp.), large and small strongyles, roundworms (ascarids), and bots (Gasterophilus spp.). The comprehensive approach contributes to improved comfort by addressing the parasitic burden that often leads to systemic discomfort such as weight loss and poor coat condition (unthriftiness).

This treatment may assist with managing factors that contribute to clinical risk for severe health events, particularly certain forms of colic linked to heavy parasite loads. By managing the underlying cause, the treatment supports functional stability of the digestive system and overall physiological well-being.


Quick Fact: Relief for Parasitic Load

This treatment may assist with managing symptom clusters that create noticeable functional strain and interfere with daily comfort.

Regulatory References

  1. Veterinary Medicines Directorate (VMD) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eqvalan Duo is strictly authorized for use in horses and other Equidae. Its official regulatory profile defines clear eligibility and non-eligibility rules based on species, age, and reproductive status.


Populations Who Must Not Use Eqvalan Duo

The medicine is contraindicated for several populations. It must not be used in mares producing milk for human consumption, which is an absolute prohibition to ensure food safety. Use in any non-equine species (such as cats, dogs, turtles, or tortoises) is also strictly prohibited due to the severe risk of toxicity from the Ivermectin component. The medicine is also contraindicated for animals with a known hypersensitivity to either of the active ingredients.


Restricted and Not Recommended Populations

Certain groups have usage limitations or lack established safety data. Use is not recommended in foals younger than two months of age and in stallions, as regulatory safety studies were not conducted in these specific populations. For pregnant mares, use during the first three months of gestation is restricted and requires a risk-benefit analysis by a veterinarian before administration. Use is generally permitted in mares after the first three months of gestation and during lactation, provided they are not producing milk for human consumption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Eqvalan Duo (Ivermectin/Praziquantel) in equids is defined by the absence of specific, formally documented drug-drug interactions.

Official Regulatory Status

According to government-approved prescribing information, including the Summary of Product Characteristics (SmPC) filed with veterinary medicines authorities, the official statement regarding co-administration is that "No data available" on interactions with other medicinal products and other forms of interactions.

Consequently, the regulatory documentation does not list specific interaction constraints across several domains:


Interaction Classification Official Labeling Statement
Contraindicated Combinations None formally listed due to interaction risk.
Pharmacokinetic Interactions No specific CYP-mediated or transporter-based interactions are documented.
Timing-Based Rules No mandatory time-separation requirements for co-administration are specified.
Food/Supplement Interactions No specific interactions with feed or supplements are officially documented.

This structure reflects that the regulatory bodies have not formally identified or specified any restrictions or required monitoring for co-administration with other veterinary medicinal products based on known interaction risks. The official label does not impose any clinical restrictions related to drug metabolism, PK/PD effects, or timing separation with other co-administered substances.

Mechanism of Action

How Eqvalan Duo Works: Dual Parasite Mechanism


Targeted Neuro-Muscular Disruption (Ivermectin)

The Ivermectin component targets glutamate-gated chloride channels ( GluCl). By acting as an agonist, it drives an influx of chloride ions ( Cl^-) across the parasite's nerve and muscle cell membranes. This mechanism causes the cells to hyperpolarize, leading to a loss of electrical excitability and resulting in flaccid paralysis and immobility in susceptible parasitic organisms.


Cellular Integrity Compromise and Spastic Contraction (Praziquantel)

The Praziquantel component utilizes a distinct mechanism by rapidly increasing the intracellular calcium ion ( Ca^2+) flux within targeted cestodes (tapeworms). This quick Ca^2+ surge causes severe damage to the parasite's tegument (outer layer) and induces uncontrollable, spastic muscle contractions (tetany). This physiological cascade results in cellular damage and detachment of the parasite.


Broadened Physiological Scope

The drug's overall physiological consequence is shaped by the additive action of these two independent mechanisms. The combination influences a broad range of physiological systems across different parasite classes, combining paralysis and structural failure to eliminate various parasites.

Dosage and Administration Information

Official Administration Guidelines

Eqvalan Duo is an oral paste for use exclusively in horses. The product is administered as a single dose using a calibrated syringe. Accurate determination of the horse's bodyweight is mandatory before treatment to ensure correct dosing, as one syringe treats up to 600 kg of bodyweight.

Dosing and Preparation

Parameter Requirement (Single Administration)
Route of Administration Oral
Dosage 200 mug/kg bodyweight (ivermectin) and 1 mg/kg bodyweight (praziquantel), equivalent to 1.29 g of paste per 100 kg bodyweight.
Syringe Adjustment The syringe's knurled ring must be set to the calculated weight marking on the plunger before use.

Administration Procedure

Administration requires the horse's mouth to be free of feed. The tip of the syringe must be inserted into the mouth at the interdental space, and the paste is to be deposited at the base of the tongue. Immediately after dosing, the horse's head must be raised for a few seconds to ensure the full quantity of the paste is consumed.

Use Constraints

Use of Eqvalan Duo is not recommended in foals younger than two months of age or in stallions, as safety studies in these categories were not conducted. It can be used in pregnant mares after the first three months of gestation and during lactation.

Recent Clinical Evidence

Eqvalan Duo: Recent Clinical Evidence


1. Evidence for Mixed Internal Parasite Infestations

The clinical evaluation for this fixed-dose combination was conducted through a series of Randomized Controlled Trials (RCTs) and Controlled Efficacy Studies, which are research necessary for regulatory review. These research efforts explored the combination's research exploration against various parasites, including strongyles, roundworms, tapeworms, and bots.

The studies primarily examined outcomes related to parasite activity by measuring Fecal Egg Counts (FECs), a metric used to quantify parasite presence. Researchers also conducted direct worm counts in certain trials as part of the assessment of parasite counts. Findings from the controlled studies reported patterns in the parasite counts measured during the study period.


2. Follow-Up and Durability of Study Outcomes

The clinical research explored the duration of observations by monitoring horses for a defined period after a single administration. This follow-up was designed to measure the time interval during which lower egg counts were observed.

For intermediate-term observations, studies reported measurements of lower egg counts extending for a period of up to approximately 10 weeks. Research has focused on documenting this period, which provides context on the stability of measured outcomes over defined time intervals.


3. Research for Specific Groups

Research explored the use of the oral paste in foals, with studies targeting animals that were two months of age and older. Findings from these studies describe the patterns observed when the combination was evaluated in pregnant mares (after the first trimester) and during lactation, as part of the research available at the time of regulatory review.


4. Known Research Limitations and Uncertainties

A specific gap exists in the research regarding the studies exploring the Ivermectin component against the encysted larval stages of small strongyles (Cyathostomins). Furthermore, a limitation of the research methodology is that common outcome measures, such as FECs, do not reliably detect all larval stages of the parasite. The broader evidence landscape also suggests that regional resistance to macrocyclic lactone compounds was observed in some studies involving certain parasite species, indicating that measured outcomes may vary depending on local parasite populations.

Key Studies & References

  1. Summary of Product Characteristics (SPC) for EQVALAN DUO - Veterinary Medicines Directorate (VMD)
  2. Small Strongyles Might be Developing Ivermectin Resistance (Research Summary on Immature Stages)

Frequently Asked Questions (FAQ)

Common questions about Eqvalan Duo (FAQ)


Q: Why is this medicine called 'Duo'?

Official product information describes Eqvalan Duo as a fixed-dose combination product. The name 'Duo' refers to the two distinct active components, Ivermectin and Praziquantel, that it contains. This fixed-dose combination structure is designed to address a broader range of parasite classes than the single-ingredient formulation.


Q: How long do the effects of Eqvalan Duo last?

Studies examining the drug's effects have documented the durability of the observed outcomes. These clinical measurements related to parasite activity, specifically lower egg counts, were reported to extend for a period of up to approximately 10 weeks following a single administration.


Q: Are there expected changes that happen after using Eqvalan Duo?

For horses with particularly heavy parasite burdens, specifically Onchocerca spp. microfilariae, post-treatment reactions may occur. These changes, which are thought to be caused by the death of the microfilariae, may include transient swelling and itching. Official documentation notes that these reactions are typically temporary and resolve within a few days.


Q: Is there a risk of resistance developing to Eqvalan Duo over time?

Official warnings advise that improper use, such as underdosing or too frequent use of dewormers from the same drug class, can contribute to the risk of resistance development over time. Specifically, resistance to the Ivermectin component (a macrocyclic lactone) has been observed in local parasite populations in some regions.


Q: How long does Eqvalan Duo stay in the system?

While detailed pharmacokinetic data is not typically summarized for the public, the regulatory profile establishes a withdrawal period of 30 days. This period indicates the time required for drug residues to fall below acceptable limits for horses intended for human meat consumption.


Q: What is the legal status of Eqvalan Duo in the United States versus Europe?

In territories such as Europe and the United Kingdom, the product is classified as a Veterinary Prescription Medicine (POM-V). This classification means that its supply is legally restricted and requires authorization from a veterinary professional.


Q: What is the difference between Eqvalan Duo and other Eqvalan products?

Eqvalan Duo is formulated as a combination medicine containing two active ingredients: Ivermectin and Praziquantel. In contrast, the original Eqvalan product contains only the single active ingredient, Ivermectin. This fixed-dose combination structure is designed to address a broader range of parasite classes than the single-ingredient formulation.


Q: What should I do if I think the drug is not working?

Official documents provide guidance in the context of suspected drug resistance. If the drug's effectiveness is questionable, official documents advise that the situation may be further investigated using appropriate tests, such as a Faecal Egg Count Reduction Test (FECRT).


Q: Can Eqvalan Duo be used in older or elderly subjects?

The regulatory documentation lists specific restrictions for foals younger than two months of age and stallions. For other equids, official product information does not specify any usage restrictions or contraindications based solely on advanced age.


Q: Does the drug have a restricted status or require a prescription?

According to the regulatory classification in authorized territories, this product is designated as a Veterinary Prescription Medicine (POM-V). This classification means that the medicine can only be supplied upon presentation of a valid veterinary prescription or equivalent authorization.


Q: What does the term 'macrocyclic lactone' mean in the context of this drug?

Macrocyclic lactone is the chemical class for the Ivermectin component of the drug. These compounds are officially described as disrupting the nervous system of susceptible parasites. This disruption leads to a loss of excitability in the parasite's nerve and muscle cells, resulting in paralysis.


Q: What are the official guidelines regarding repeated use of Eqvalan Duo?

Official precautions advise that the product is intended to be used as part of a rotational parasite control program. To manage the risk of resistance, official guidelines note that avoiding the too frequent and repeated use of anthelmintics from the same chemical class over prolonged periods is part of a responsible program.


Q: Is Eqvalan Duo known to cause sensitivity reactions in certain breeds or types of subjects?

The official safety label includes strong warnings related to accidental ingestion by non-target species due to the concentration of Ivermectin. Specific precautions are noted for animals like dogs (especially breeds such as Collies), cats, turtles, and tortoises, which may experience severe adverse effects if they ingest the paste.


Q: Is there any research on Eqvalan Duo's long-term safety profile?

Research available during the regulatory review process primarily focused on the drug's effectiveness and safety over the intermediate term. Studies tracked specific outcome measures, such as lower egg counts, for periods extending up to about 10 weeks. Research evidence regarding the drug's safety profile over many months or years is less emphasized in the publicly available summaries.


Q: What is the difference between 'contraindication' and 'warning' for this drug?

Regulatory documents employ specific language to define restrictions on use. A contraindication represents an absolute prohibition for using the product (e.g., in foals under two months). In contrast, a statement that use is not recommended or a warning indicates a limitation, often because safety studies were not conducted in that specific population (e.g., in stallions).


Q: Is there a human safety concern if a person accidentally contacts Eqvalan Duo?

The official safety information states that handlers are expected to wash their hands thoroughly after use and avoid contact with their skin and eyes, as the product may cause irritation. The label also specifies that handlers should not smoke, eat, or drink while administering the paste.

How should Eqvalan Duo be stored and disposed of?

Storage and Disposal Requirements for Eqvalan Duo Oral Paste

Eqvalan Duo oral paste must be stored in its original container, and the cap on the syringe must be replaced immediately after use. The product has a labeled shelf life of 3 years as packaged for sale. After the first opening of the immediate packaging, the product remains stable for 2 years.

Disposal and Environmental Protection

Due to the hazard posed by its active ingredients to fish and other aquatic organisms, the product must not enter water courses and should not be disposed of via wastewater. Unused or expired Eqvalan Duo must be disposed of according to local requirements and applicable national collection systems, such as designated take-back schemes. The product should also be stored out of the reach and sight of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eqvalan Duo found in:

A-Z Index: